MGRX vs. BRTX, GBNHF, OTRK, PULM, TENX, SHPH, IBIO, LFLY, ASLN, and INBS
Should you be buying Mangoceuticals stock or one of its competitors? The main competitors of Mangoceuticals include BioRestorative Therapies (BRTX), Greenbrook TMS (GBNHF), Ontrak (OTRK), Pulmatrix (PULM), Tenax Therapeutics (TENX), Shuttle Pharmaceuticals (SHPH), iBio (IBIO), Leafly (LFLY), ASLAN Pharmaceuticals (ASLN), and Intelligent Bio Solutions (INBS). These companies are all part of the "medical" sector.
Mangoceuticals (NASDAQ:MGRX) and BioRestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.
Mangoceuticals and BioRestorative Therapies both received 0 outperform votes by MarketBeat users.
Mangoceuticals has higher revenue and earnings than BioRestorative Therapies.
Mangoceuticals has a net margin of -1,260.81% compared to BioRestorative Therapies' net margin of -9,873.97%. BioRestorative Therapies' return on equity of -114.84% beat Mangoceuticals' return on equity.
In the previous week, Mangoceuticals and Mangoceuticals both had 3 articles in the media. Mangoceuticals' average media sentiment score of 0.72 beat BioRestorative Therapies' score of 0.14 indicating that Mangoceuticals is being referred to more favorably in the media.
56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 69.4% of BioRestorative Therapies shares are owned by institutional investors. 46.4% of Mangoceuticals shares are owned by company insiders. Comparatively, 21.6% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Mangoceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 62.12, meaning that its share price is 6,112% more volatile than the S&P 500.
Summary
Mangoceuticals and BioRestorative Therapies tied by winning 5 of the 10 factors compared between the two stocks.
Get Mangoceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mangoceuticals Competitors List
Related Companies and Tools
